*Pseudomonas*

This represents the fourth most studied organism (11%) for AMR in Nigeria and had a spread similar to *E. coli* research (Figures 1 and 2). The distribution of the studies of all antimicrobials used revealed that 38 antimicrobials were used to test the AMR in *Pseudomonas* isolates (Figure 4d). Unlike other organisms, there were no antibiotics from the 38 tested with *Pseudomonas* without resistance (Figure 4d). There was "very high resistance" by all *Pseudomonas* studied to amoxicillin, amoxicillin-clavunanic acid, ampicillin-cloxacillin, cefuroxime, meropenem, mezlocillin, and teicoplanin and "high resistance" to cefotaxime, erythromycin, nitrofuran, piperacillin, tobramycin, ticarcillin clavulanate, cefoperazone, lomeofloxacin, and fosfomycin (Figure 4d). All reports of studies that tested chloramphenicol with *Pseudomonas* spp. had 75% of them to be "very high resistance" and the remaining 25% of reports were "high resistance". Various resistance patterns were observed in the remaining antibiotics studied (Figure 4d, Figure S16).

## *Klebsiella*

This is the fifth most studied organism and contributed 9% of the overall studies for AMR in Nigeria, with spread across four out of the six geopolitical zones (South West, South South, North West, and North Central) of Nigeria (Figures 1 and 2). The distribution pattern of the appearance of all antimicrobials used revealed that 33 antimicrobials were used to test the AMR of *Klebsiella* isolates (Figure 4e). All the *Klebsiella* spp. studied demonstrated "no resistance" to amikacin, aztreonam, cefotaxime, ceftazidime, piperacillin-texobactam, tobramycin, mezlocillin, ticarcillin clavulanate, and cefoperazone and "low resistance" to cefuroxime and levofloxacin; but, "very high resistance" to ampicillin-cloxacillin, nitrofuran, lomeofloxacin, teicoplanin, fosfomycin, and sulphadimidine (Figure 4a). Meanwhile, it demonstrated a high proportion of "very high resistance" in amoxicillin (60%), amoxicillin-clavunanic acid (75%), ampicillin (75%), chloramphenicol (50%), erythromycin (50%), neomycin (33%), and co-trimoxazole (80%) (Figure 4e, Figure S17).
